OCS vs OGEN

Oculis Holding AG vs Oragenics Inc. — Valuation Comparison 2026

OCS

Biotechnology
Oculis Holding AG
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$29.65
Last close
Models
8/13
Active
VS

OGEN

Biotechnology
Oragenics Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$0.60
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType OCS Fair ValueOCS Upside OGEN Fair ValueOGEN Upside
Bayesian DCF Intrinsic $8.55 -71.2% $0.90 +49.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.28 -99.0% $0.14 -76.9%
Dynamic NAV Asset-Based $2.25 -92.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OCS vs OGEN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OCS vs OGEN — Which Stock Is More Undervalued?

OGEN scores higher with a 4.5/10 quality rating vs OCS's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oculis Holding AG (OCS) and Oragenics Inc. (OGEN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OCS currently trades at $29.65 with a QOC of 3.8/10, while OGEN trades at $0.60 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).